These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 12827033)

  • 41. Renal responses to three types of renin-angiotensin system blockers in patients with diabetes mellitus on a high-salt diet: a need for higher doses in diabetic patients?
    Hollenberg NK; Fisher ND; Nussberger J; Moukarbel GV; Barkoudah E; Danser AH
    J Hypertens; 2011 Dec; 29(12):2454-61. PubMed ID: 22002336
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A clinical trial in type 2 diabetic nephropathy.
    Lewis EJ; Hunsicker LG; Rodby RA;
    Am J Kidney Dis; 2001 Oct; 38(4 Suppl 1):S191-4. PubMed ID: 11576953
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Long-term effects of irbesartan and atenolol on the renin-angiotensin-aldosterone system in human primary hypertension: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA).
    Malmqvist K; Ohman KP; Lind L; Nyström F; Kahan T
    J Cardiovasc Pharmacol; 2003 Dec; 42(6):719-26. PubMed ID: 14639093
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy of Zofenopril vs. Irbesartan in Combination with a Thiazide Diuretic in Hypertensive Patients with Multiple Risk Factors not Controlled by a Previous Monotherapy: A Review of the Double-Blind, Randomized "Z" Studies.
    Omboni S; Malacco E; Napoli C; Modesti PA; Manolis A; Parati G; Agabiti-Rosei E; Borghi C
    Adv Ther; 2017 Apr; 34(4):784-798. PubMed ID: 28260186
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Association between human atrial natriuretic peptide Val7Met polymorphism and baseline blood pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in rural Chinese patients with essential hypertension.
    Zhang S; Mao G; Zhang Y; Tang G; Wen Y; Hong X; Jiang S; Yu Y; Xu X
    Clin Ther; 2005 Nov; 27(11):1774-84. PubMed ID: 16368448
    [TBL] [Abstract][Full Text] [Related]  

  • 46. 24-hour blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. Irbesartan Multicenter Investigators' Group.
    Fogari R; Ambrosoli S; Corradi L; Degli Esposti E; Mos L; Nami R; Nicrosini F; Pessina AC; Salvetti A; Vaccarella A; Zanchetti A; Martin A; Reeves RA
    J Hypertens; 1997 Dec; 15(12 Pt 1):1511-8. PubMed ID: 9431859
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Short-term dietary salt supplementation blunts telmisartan induced increases in plasma renin activity in hypertensive patients with type 2 diabetes mellitus.
    Chen AX; Jerums G; Baqar S; Lambert E; Somarajah G; Thomas G; O'Callaghan C; MacIsaac RJ; Ekinci EI
    Clin Sci (Lond); 2015 Sep; 129(5):415-22. PubMed ID: 25849646
    [TBL] [Abstract][Full Text] [Related]  

  • 49. BP goal achievement in patients with uncontrolled hypertension : results of the treat-to-target post-marketing survey with irbesartan.
    Schrader J; Bramlage P; Lüders S; Thoenes M; Schirmer A; Paar DW
    Clin Drug Investig; 2007; 27(11):783-96. PubMed ID: 17914897
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Hormonal profile and participation of nitric oxide in salt-sensitive and salt-resistant essential arterial hypertension].
    Gómez-Fernández P; Moreno VG; Cornejo M; Vargas JC; García-Barroso C; Velasco G; Almaraz M
    Nefrologia; 2000; 20(5):415-23. PubMed ID: 11100662
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A multicenter, randomized, double-blind study of the antihypertensive efficacy and tolerability of irbesartan in patients aged > or = 65 years with mild to moderate hypertension.
    Lacourcière Y
    Clin Ther; 2000 Oct; 22(10):1213-24. PubMed ID: 11110232
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing.
    Hermida RC; Ayala DE; Mojón A; Fontao MJ; Fernández JR
    Chronobiol Int; 2011 Aug; 28(7):601-10. PubMed ID: 21823969
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Importance of the renin system for determining blood pressure fall with acute salt restriction in hypertensive and normotensive whites.
    He FJ; Markandu ND; MacGregor GA
    Hypertension; 2001 Sep; 38(3):321-5. PubMed ID: 11566898
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy, safety and tolerability of valsartan 80 mg compared to irbesartan 150 mg in hypertensive patients on long-term hemodialysis (VALID study).
    Leidig M; Bambauer R; Kirchertz EJ; Szabã T; Handrock R; Leinung D; Baier M; Schmieder RE
    Clin Nephrol; 2008 Jun; 69(6):425-32. PubMed ID: 18538118
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Blunted sleep-time relative blood pressure decline increases cardiovascular risk independent of blood pressure level--the "normotensive non-dipper" paradox.
    Hermida RC; Ayala DE; Mojón A; Fernández JR
    Chronobiol Int; 2013 Mar; 30(1-2):87-98. PubMed ID: 23039824
    [TBL] [Abstract][Full Text] [Related]  

  • 56. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G;
    Clin Ther; 2012 Aug; 34(8):1720-34.e3. PubMed ID: 22853847
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Irbesartan effects on renal function in patients with renal impairment and hypertension: a drug-withdrawal study.
    De Rosa ML; de Cristofaro A; Rossi M; Baiano A; Cardace P; Albanese L; Vigorito C
    J Cardiovasc Pharmacol; 2001 Sep; 38(3):482-9. PubMed ID: 11486253
    [TBL] [Abstract][Full Text] [Related]  

  • 58. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan. Irbesartan/Losartan Study Investigators.
    Oparil S; Guthrie R; Lewin AJ; Marbury T; Reilly K; Triscari J; Witcher JA
    Clin Ther; 1998; 20(3):398-409. PubMed ID: 9663357
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A randomised, double-blind comparison of the angiotensin II receptor antagonist, irbesartan, with the full dose range of enalapril for the treatment of mild-to-moderate hypertension.
    Mimran A; Ruilope L; Kerwin L; Nys M; Owens D; Kassler-Taub K; Osbakken M
    J Hum Hypertens; 1998 Mar; 12(3):203-8. PubMed ID: 9579771
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 24-hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan.
    Tofé Povedano S; García De La Villa B
    J Clin Hypertens (Greenwich); 2009 Aug; 11(8):426-31. PubMed ID: 19695030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.